5月20日，派格生物医药-B盘中上涨8.37%，报17.47港元，成交额7232.33万港元。
消息面上，公司核心产品派达康（维培那肽注射液）商业化进程加速。此前公司与腾瑞制药就派达康中国大陆独家商业化签署战略合作协议，腾瑞制药将支付合计约1.4亿港币权益金，双方确立累计销售超100亿元人民币的核心目标。5月12日，方舟健客与腾瑞制药达成战略合作，派达康将于近期在其互联网医院平台全网首发，标志着该GLP-1创新药正式进入商业化放量阶段。受上述利好驱动，该股上周曾单日飙升逾100%，当前仍处于资金活跃博弈期。
派格生物医药是一家从事慢性病创新疗法研发的公司，核心产品PB-119为自主开发的长效GLP-1受体激动剂，主要用于治疗2型糖尿病及肥胖症等代谢疾病。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.